Author: Tom Wilemon
Trial for colorectal cancer drug reaches primary endpoint
Aug. 17, 2022—A new therapy for metastatic colorectal cancer that has been granted fast track designation by the U.S. Food and Drug Administration has met its primary endpoint of overall survival in a phase 3 clinical trial.
Couple’s gift helps support immunotherapy research
Aug. 11, 2022—Luke and Susan Simons have endowed a new directorship that will support research so that more people can benefit from immunotherapies.
Study that investigated whether three smoking cessation drugs could reduce alcohol intake yields unexpected finding
Aug. 5, 2022—A Vanderbilt study of three proven smoking cessation treatments suggests these medications could play an important role to reduce alcohol use and smoking at the same time.
Study reveals need for matching targeted therapies with EGFR subtypes
Jul. 28, 2022—A Vanderbilt study suggests that clinicians should take a deeper dive into distinguishing EGFR mutations when prescribing targeted therapies for non-small-cell lung cancers.
Holowatyj named chair of scientific advisory board for ACPMP Research Foundation
Jul. 15, 2022—Vanderbilt's Andreana Holowatyj, PhD, MSCI, has been named the inaugural chair of the scientific advisory board for the Appendix Cancer Pseudomyxoma Peritonei Research Foundation.
Smokers have better quit rates with hospital-based interventions than quitline help, but study indicates need for longer follow-up
Jun. 28, 2022—A health care system model that offered tobacco cessation treatment to smokers being discharged from a hospital produced a higher rate of tobacco abstinence during the three-month program than referral to a state-based telephone quitline, but the advantage disappeared at six months when both treatments produced comparable quit rates, researchers have found.
Study reveals how gastric cancer forms, suggests preventive treatment
Jun. 23, 2022—Eunyoung Choi, PhD, assistant professor of Surgery, and colleagues identified for the first time that Trop2+/CD133+/CD166+ dysplastic stem cells are a key source of clonal evolution of dysplasia to multiple types of gastric cancer.
Choi, Short receive AGA Research Foundation Awards
Jun. 2, 2022—Two Vanderbilt researchers have received awards from the AGA Foundation, the charitable arm of the American Gastroenterological Association.
Conquer Cancer awards given to five hematology-oncology fellows
May. 26, 2022—Five Vanderbilt University Medical Center hematology and oncology fellows will receive awards from Conquer Cancer, the ASCO Foundation, during the 2022 American Society of Clinical Oncology Annual Meeting in Chicago, June 3-7.
VICC Scientific Retreat focuses on lung cancer
May. 5, 2022—by Tom Wilemon Speakers at the Vanderbilt-Ingram Cancer Center (VICC) 23rd Annual Scientific Retreat celebrated “Advances in Lung Cancer Research” but noted that too many people with the disease are not benefiting from those achievements. “Lung cancer is our leading cause of cancer mortality. Twenty-nine percent of our total cancers are lung cancer. That’s the...
Study casts doubt on impact of menthol-flavored tobacco ban
Apr. 21, 2022—Vanderbilt research finds that a ban on the sale of menthol-flavored cigarettes that the U.S. Food and Drug Administration (FDA) is on track to implement may have unintended consequences.
Biltibo receives career development award to support hematology research
Apr. 21, 2022—Vanderbilt's Eden Biltibo, MD, a clinical fellow in the Division of Hematology and Oncology, has been selected for the 2022 ASH-CIBMTR-ASTCT Career Development Award.
